[SMLE] The recognition, physiology, and treatment of Lambert-Eaton myasthenic syndrome
Posté : 21 juin 2025 12:00
Dis Mon. 2025 Jun 20:101967. doi: 10.1016/j.disamonth.2025.101967. Online ahead of print.
ABSTRACT
Lambert-Eaton myasthenic syndrome (LEMS) is a rare disease affecting the neuromuscular junction. It causes weakness due to the failure of acetylcholine transmission at the neuromuscular junction. It is also responsible for autonomic symptoms due to the loss of acetylcholine release at autonomic nerves resulting in most often dry mouth, but also impotence, sweating disturbance and orthostatic hypotension. The underlying pathology is split nearly evenly as either paraneoplastic or autoimmune. The challenges in making a diagnosis result in a delay which may correlate with a later initiation of cancer therapy in those with cancers, predominantly small cell lung cancer. There are effective treatments for symptoms of LEMS that work directly at the neuromuscular junction, as well as treatments for the cancer if present. Various types of immunosuppression can be beneficial for both paraneoplastic (T LEMS) and non-tumor LEMS (NT LEMS).
PMID:40544116 | DOI:10.1016/j.disamonth.2025.101967
Source: https://pubmed.ncbi.nlm.nih.gov/4054411 ... t9+e462414